Drugs / OPK-88003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03406377 | Apr 2018 → Mar 2019 | type 2 diabetes mellitus | OPKO Health, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-04-12 | OPKO Health, Inc. | Results OPKO Reports Additional Oxyntomodulin, OPK-88003, Results From Phase 2 Diabetes and Obesity Trial opko.com ↗
OPKO Health, Inc. (NASDAQ: OPK) today reported additional results from the per protocol patient population from the Phase 2 dose escalation trial of OPK-88003 to treat type 2 diabetes and obesity. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-04-12 | OPKO Health, Inc. | OPKO Reports Additional Oxyntomodulin, OPK-88003, Results From Phase 2 Diabetes and Obesity Trial opko.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPK-88003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03406377 ↗ |
| Route | Subcutaneous | “OPK-88003 subcutaneous injection” NCT03406377 ↗ |